Abbott Clears Next-Gen AI-Powered Coronary Imaging Platform in U.S. and Europe

Event summary

  • Abbott received FDA clearance and CE Mark for Ultreon™ 3.0, an AI-powered coronary imaging platform, on April 28, 2026.
  • Ultreon 3.0 integrates high-resolution OCT imaging with AI-automated insights for real-time decision-making during PCI procedures.
  • The platform features a one-second OCT pullback, offering higher resolution than IVUS and minimizing contrast use, beneficial for patients with kidney disease.
  • Over 600,000 PCIs are performed annually in the U.S. and more than 885,000 in Europe, representing a significant market opportunity.

The big picture

Abbott's Ultreon 3.0 represents a significant leap in AI-powered coronary imaging, addressing the growing demand for precision-guided interventions in complex PCI procedures. The platform's ability to minimize contrast use is particularly relevant for the 25% of coronary artery disease patients with kidney disease. This approval solidifies Abbott's leadership in AI-driven cardiovascular solutions, positioning the company to capture a larger share of the $6 billion global intravascular imaging market.

What we're watching

Adoption Pace
How quickly hospitals and cardiologists will integrate Ultreon 3.0 into their workflows, given its advanced AI capabilities.
Competitive Response
Whether competitors like Boston Scientific or Philips will accelerate their own AI-powered imaging solutions.
Clinical Outcomes
The impact of Ultreon 3.0 on patient outcomes, particularly in complex PCI cases, which could drive further market penetration.